|
| SMALLPOX | SMALLPOX ERADICATED |
| ORAL POLIO (OPV) | POLIO REGIONALLY ELIMINATED
A SAFER VERSION (INACTIVATED POLIO VACCINE) WAS AVAILABLE THAT REPLACED THE LIVE ATTENUATED ORAL VACCINE IN INDUSTRIALIZED COUNTRIES |
| ROTAVIRUS (ROTASHIELD®) | SAFETY CONCERNS (IMPLICATED AS A CAUSE OF INTUSSUSCEPTION IN INFANTS) |
| LYME DISEASE | SAFETY CONCERNS (REAL AND/OR PERCEIVED AUTOIMMUNE SIDE EFFECTS) |
| ECONOMIC REASONS (ACTUAL MARKET PROVED MUCH SMALLER THAN ORIGINALLY ANTICIPATED, EXPENSIVE LITIGATION) |
| ADENOVIRUS | ECONOMIC REASONS (THE COSTS OF ADHERING TO NEW GOOD MANUFACTURING PRACTICE RULES WERE PROHIBITIVE FOR THE MANUFACTURER) |
| HEPATITIS B (PLASMA-DERIVED) | PERCEIVED SAFETY RISKS (HUMAN PLASMA WAS SEEN AS UNSAFE FOR VACCINE PRODUCTION IN THE WAKE OF THE DISCOVERY OF AIDS IN THE 1980S)
REPLACED BY AN IMPROVED PRODUCT (RECOMBINANT HBV VACCINE) |
| HBV RECOMBINANT | SUSPENDED FROM USE IN SCHOOL-AGED CHILDREN IN FRANCE
PERCEIVED SAFETY RISKS (UNSUBSTANTIATED LINKS TO MULTIPLE SCLEROSIS) |
| WHOLE CELL PERTUSSIS | REMOVED FROM THE MARKET IN SWEDEN BECAUSE OF SAFETY CONCERNS (REPLACED IN OTHER MARKETS WITH THE ACELLULAR PERTUSSIS VACCINE) |
| KILLED MEASLES | SAFETY CONCERNS (ATYPICAL MEASLES) |
| HIB POLYSACCHARIDE | REPLACED BY AN IMPROVED PRODUCT (HIB CONJUGATE VACCINE) |
| NEURAL TISSUE-DERIVED RABIES | REPLACED BY AN IMPROVED PRODUCT (CELL CULTURE-DERIVED VACCINE) |
| INTRANASAL INACTIVATED INFLUENZA (ADJUVANTED WITH WTLT) | SAFETY CONCERNS (BELL'S PALSY) |
The Pfizer Covid Vaccine has adverse event ratios orders of magnitude worse then previous vaccines pulled from the market over safety concerns. 
